Evaluation of the subcutaneous administration of 30 mg of S 78989 versus placebo and evaluation of the subcutaneous administration of 60 mg of S 78989 versus placebo on the reduction of arterial wall inflammation in patients with marked atherosclerotic plaque inflammation. A 28-weeks, randomised, double-blind, parallel-group, placebo controlled, international multicentre exploratory pilot study

Trial Profile

Evaluation of the subcutaneous administration of 30 mg of S 78989 versus placebo and evaluation of the subcutaneous administration of 60 mg of S 78989 versus placebo on the reduction of arterial wall inflammation in patients with marked atherosclerotic plaque inflammation. A 28-weeks, randomised, double-blind, parallel-group, placebo controlled, international multicentre exploratory pilot study

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2014

At a glance

  • Drugs Gevokizumab (Primary)
  • Indications Acute coronary syndromes; Atherosclerosis
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors IRIS
  • Most Recent Events

    • 21 Sep 2013 Planned number of patients changed from 45 to 90 as reported by European Clinical Trials Database record.
    • 16 Mar 2013 Official title amended as reported by European Clinical Trials Database record.
    • 29 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top